This is a routine shelf registration following a recent capital raise. The lack of company proceeds and recent strong financing suggest this is administrative, not a sign of immediate fundraising need. Monitor for actual issuance under the shelf, which could create dilution.
RLMD drugs
RLMD drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 6 $6.90entry
- T+1 · 7mo ago −2.17%α −2.24% · $6.75
- T+5 · 7mo ago +6.96%α +2.82% · $7.38
- T+20 · 7mo ago +7.39%α −1.59% · $7.41
- T+60 · 5mo ago −7.39%α −20.86% · $6.39
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Relmada Therapeutics filed an S-3 shelf registration to register the resale of 33,685,096 shares of common stock by selling stockholders, including 29,474,569 shares and 4,210,527 shares issuable upon exercise of pre-funded warrants, from a recent $160 million PIPE financing. The company will not receive proceeds from the resale, but the registration supports future capital raising flexibility. This follows strong clinical data for NDV-01 and a robust cash position extending into 2029.
Key Financial Metrics
Key Facts
- S-3 shelf registration filed for resale of 33,685,096 shares by selling stockholders from a March 2026 PIPE financing
- Offering includes 29,474,569 shares of common stock and 4,210,527 shares issuable upon exercise of pre-funded warrants
- Total offering value registered is $215.9 million based on a $6.41 share price
- Company will not receive any proceeds from the resale of shares by selling stockholders
- Recent $160 million PIPE financing completed in March 2026 strengthens cash position to fund operations through 2029
- Positive 12-month Phase 2 data for NDV-01 in bladder cancer showed 76% durable complete response rate
Financial Impact
The registration covers $215.9 million of shares for resale, but the company receives no proceeds. The recent $160 million PIPE financing provides significant capital.
Risk Factors
- Future issuance under the shelf could lead to shareholder dilution
- Biotech clinical development carries inherent risks of trial failure
- Pre-funded warrants could be exercised, increasing share count
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 11 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001213900-26-039967 |
| Document: ea028291501ex-fee.htm | 0001213900-26-039967 |
| Document: ea028291501ex5-1.htm | 0001213900-26-039967 |
| Document: ea028291501ex23-1.htm | 0001213900-26-039967 |
| Document: ea028291501ex23-2.htm | 0001213900-26-039967 |
| Document: ea028291501ex3-1v.htm | 0001213900-26-039967 |
| Document: ea028291501ex3-1vi.htm | 0001213900-26-039967 |
| Document: ea028291501ex3-1vii.htm | 0001213900-26-039967 |
| Document: 0001213900-26-039967-index-headers.html | 0001213900-26-039967 |
| Document: 0001213900-26-039967-index.html | 0001213900-26-039967 |
| Document: 0001213900-26-039967.txt | 0001213900-26-039967 |
Track record
11 reports on RLMD
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +38.81% at T+60 after the May 13, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $3.54 Now $3.61 −1.98% settles Dec 15
- Nov 16, 2026today 8-K Neutral 3/10 Entry $4.16 Now $3.61 −13.23% settles Dec 15
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $4.21 Now $3.61 −14.25% settles Dec 14
- Sep 11, 20269w ago Insider Cluster Bullish 6/10 Entry $4.52 to $3.39 Now $3.61 −20.13% ▼ −25.00% −26.87% vs SPY
- May 13, 202626w ago S-3ASR Bearish 6/10 Entry $7.42 to $6.65 Now $3.61 +51.35% ▲ +10.38% +9.52% vs SPY
- May 12, 202626w ago 8-K Neutral 4/10 Entry $7.49 to $6.52 Now $3.61 −51.80% ▼ −12.95% −12.34% vs SPY
- Apr 17, 202630w ago DEFA14A Neutral 3/10 Entry $7.37 to $6.34 Now $3.61 −51.02% ▼ −13.98% −18.18% vs SPY
- Apr 3, 202632w ago S-3 Neutral 3/10 Viewing Entry $6.90 to $7.41 Now $3.61 −47.68% ▲ +7.39% −1.59% vs SPY
- Mar 19, 202634w ago Press Release Bullish 8/10 Entry $6.07 to $7.37 Now $3.61 −40.53% ▲ +21.42% +12.10% vs SPY
- Mar 12, 202635w ago Press Release Neutral 3/10 Entry $6.15 to $7.29 Now $3.61 −41.30% ▲ +18.54% +16.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers